As of June 30, 2026, Balsm Alofoq Medical Company carries a market capitalization of 60.00M, placing it among publicly traded companies globally. Its enterprise value stands at 50.08M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 60.00M |
| Enterprise Value | 50.08M |
As of June 30, 2026, Balsm Alofoq Medical Company has 2.50M shares outstanding.
| Shares Outstanding | 2.50M |
These figures are as of June 30, 2026.
| PB Ratio | 1.89 |
| P/TBV Ratio | 1.89 |
As of June 30, 2026, Balsm Alofoq Medical Company maintains a current ratio of 7.67, meaning it holds 7.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 7.67 |
| Quick Ratio | 4.66 |
| Debt / Equity | 9.49 |
As of the close on November 17, 2026, Balsm Alofoq Medical Company's stock has declined approximately 17.29% over the past 52 weeks. The 50-day moving average sits at 22.86, while the 200-day moving average is 25.56.
| 52-Week Price Change | -17.29% |
| 50-Day Moving Average | 22.86 |
| 200-Day Moving Average | 25.56 |
As of June 30, 2026, Balsm Alofoq Medical Company holds 12.93M in cash and equivalents against 3.01M in total debt, resulting in a net debt position of -12.93M. Total book value stands at 31.70M, with working capital of 18.51M providing operational flexibility.
| Cash & Cash Equivalents | 12.93M |
| Total Debt | 3.01M |
| Net Debt | -12.93M |
| Equity (Book Value) | 31.70M |
| Book Value Per Share | 12.68 |
| Working Capital | 18.51M |
Balsm Alofoq Medical Company's most recent stock split took place on December 22, 2025 with a 1:2 split ratio.
| Last Split Date | 12/22/2025 |
| Split Ratio | 1:2 |
Already premium?